100000 - Document - Document and Entity Information
link:presentationLink
link:calculationLink
link:definitionLink
100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
100020 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail) 2
link:presentationLink
link:calculationLink
link:definitionLink
100030 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
100040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
100050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
link:presentationLink
link:calculationLink
link:definitionLink
100060 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDER'S EQUITY
link:presentationLink
link:calculationLink
link:definitionLink
995455 - Disclosure - Nature of Business
link:presentationLink
link:calculationLink
link:definitionLink
995465 - Disclosure - Basis of Presentation
link:presentationLink
link:calculationLink
link:definitionLink
995475 - Disclosure - Summary of Significant Accounting Policies
link:presentationLink
link:calculationLink
link:definitionLink
995485 - Disclosure - Significant Collaborative Research and License Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995495 - Disclosure - Net Loss per Share Attributable to Common Stockholders
link:presentationLink
link:calculationLink
link:definitionLink
995505 - Disclosure - Significant Agreements
link:presentationLink
link:calculationLink
link:definitionLink
995515 - Disclosure - Other Receivables
link:presentationLink
link:calculationLink
link:definitionLink
995525 - Disclosure - Fair Value Measurements
link:presentationLink
link:calculationLink
link:definitionLink
995535 - Disclosure - Prepaid Expenses and Other Current Assets
link:presentationLink
link:calculationLink
link:definitionLink
995545 - Disclosure - Inventory
link:presentationLink
link:calculationLink
link:definitionLink
995555 - Disclosure - Accrued Expenses and Other Current Liabilities
link:presentationLink
link:calculationLink
link:definitionLink
995565 - Disclosure - Royalty Interest Financing Liability
link:presentationLink
link:calculationLink
link:definitionLink
995575 - Disclosure - Stock-Based Compensation
link:presentationLink
link:calculationLink
link:definitionLink
995585 - Disclosure - Loan Payable
link:presentationLink
link:calculationLink
link:definitionLink
995595 - Disclosure - Stockholders' Equity
link:presentationLink
link:calculationLink
link:definitionLink
995605 - Disclosure - Commitments and Contingencies
link:presentationLink
link:calculationLink
link:definitionLink
995615 - Disclosure - Subsequent Events
link:presentationLink
link:calculationLink
link:definitionLink
995625 - Disclosure - Segment Reporting
link:presentationLink
link:calculationLink
link:definitionLink
995635 - Disclosure - Summary of Significant Accounting Policies (Policies)
link:presentationLink
link:calculationLink
link:definitionLink
995645 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995655 - Disclosure - Fair Value Measurements (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995665 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995675 - Disclosure - Inventory (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995685 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995695 - Disclosure - Royalty Interest Financing Liability (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995705 - Disclosure - Stock-Based Compensation (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995715 - Disclosure - Loan Payable (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995725 - Disclosure - Stockholders' Equity (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995735 - Disclosure - Segment Reporting (Tables)
link:presentationLink
link:calculationLink
link:definitionLink
995745 - Disclosure - Nature of Business - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995755 - Disclosure - Basis of Presentation (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995765 - Disclosure - Summary of Significant Accounting Policies (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995775 - Disclosure - Significant Collaborative Research and License Agreements - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995785 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995795 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995805 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995815 - Disclosure - Significant Agreements - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995825 - Disclosure - Other Receivables (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995835 - Disclosure - Fair Value Measurements - Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995845 - Disclosure - Fair Value Measurements - Summary of Fair Value (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995855 - Disclosure - Fair Value Measurements - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995865 - Disclosure - Fair Value Measurements - Summary of Available-for-Sale Securities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995875 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expenses and Other Current Assets (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995885 - Disclosure - Inventory - Schedule of Consisted Inventries (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995895 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995905 - Disclosure - Royalty Interest Financing Liability (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995915 - Disclosure - Royalty Interest Financing Liability - Schedule of Term Loan Payables (Details)
link:presentationLink
link:calculationLink
link:definitionLink
995925 - Disclosure - Stock-Based Compensation - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995935 - Disclosure - Stock-Based Compensation - Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995945 - Disclosure - Stock-Based Compensation - Compensation Expense by Type of Award (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995955 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995965 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Units Activity (Detail) (Parenthetical)
link:presentationLink
link:calculationLink
link:definitionLink
995975 - Disclosure - Loan Payable - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995985 - Disclosure - Stockholders' Equity - Summary of Changes in Stockholders' Equity (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
995995 - Disclosure - Stockholders' Equity - Summary of Changes in Stockholders' Equity (Parenthetical) (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996005 - Disclosure - Stockholders' Equity - Additional Information (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996015 - Disclosure - Stockholders' Equity - Schedule of Common Stock Reserved for Future Issuance (Detail)
link:presentationLink
link:calculationLink
link:definitionLink
996025 - Disclosure - Commitments and Contingencies (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996035 - Disclosure - Subsequent Events (Additional Information) (Details)
link:presentationLink
link:calculationLink
link:definitionLink
996045 - Disclosure - Segment Reporting - Schdule of Operating Financial Result (Details)
link:presentationLink
link:calculationLink
link:definitionLink
Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale, Total
Proceeds from sales and maturities of short-term investments
Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale
Collaboration Revenue
Collaborative Arrangement, Accounting Policy [Policy Text Block]
Statement [Line Items]
Statement [Line Items]
Entity Address, Address Line Three
Entity Address, Address Line Three
Debt Instrument
Debt Instrument [Axis]
Clinical Trial [Member]
Clinical Trial [Member]
Clinical trial.
Warrant issued
Class Of Warrant Or Right Issued
Class of warrant or right issued.
Accounts Receivable
Increase (Decrease) in Accounts Receivable
Accounts Receivable
Plan Name
Plan Name [Domain]
Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]
Research and Development, Contract to Perform for Others [Table]
Schedule of Common Stock Reserved for Future Issuance
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]
Entity Address, Postal Zip Code
Entity Address, Postal Zip Code
AOCI, Debt Securities, Available-for-Sale, Adjustment, after Tax
Accumulated other comprehensive gain
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]
Fair Value, Recurring and Nonrecurring [Table]
State of incorporation
Entity Incorporation, State or Country Code
Entity Incorporation, State or Country Code
Less: Significant and other segment expenses
Costs and Expenses [Abstract]
Revenue:
Revenues [Abstract]
Number of operating segments
Number of Operating Segments
Disclosure of accounting policy for Significant risks and uncertainties.
Significant Risks And Uncertainties Policy [Text Block]
Significant Risks and Uncertainties
Ending balance, shares
Beginning balance, shares
Shares, Outstanding
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Axis]
Fair value of restricted stock units vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value
Default interest rate
Additional Default Interest Rate
Additional default interest rate.
Significant Other Observable Inputs Level 2 [Member]
Fair Value, Inputs, Level 2 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Fair Value Measurement
Fair Value Measurement [Domain]
Offering price per share.
Offering Price Per Share
Offering price
Long-Term Debt, Current Maturities
Long-Term Debt, Current Maturities, Total
Royalty interest financing liability, less current portion
Commitments and Contingencies
Commitments and Contingencies Disclosure [Text Block]
Schedule Of Stock By Class [Table]
Stock, Class of Stock [Table]
Summary of Fair Value
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
UCB License Agreement [Member]
Ucb License Agreement [Member]
UCB license agreement.
Product and Service [Axis]
Loss Contingency, Loss in Period
Collaboration loss
Lender Name
Lender Name [Axis]
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Domain]
Reimbursable costs
Reimbursable Costs
Reimbursable costs.
Interest Expense, Nonoperating, Total
Interest Expense, Nonoperating
Other interest expense
Stockholders' Equity
Equity [Text Block]
Title of Individual
Title and Position [Axis]
Percentage of Funded Amount
Percentage of Funded Amount
Percentage of Funded Amount
Sale of Stock
Sale of Stock [Domain]
Prepayment Fee
Prepayment Fee
Entity Central Index Key
Entity Central Index Key
Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]
Summary in Compensation Expense by Type of Award
Schedule Of Available For Sale Securities [Line Items]
Debt Securities, Available-for-Sale [Line Items]
Warrant [Member]
Warrant [Member]
Share-based compensation, stock options cancelled
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Upfront Payment
Upfront Payment
Upfront Payment
Changes in operating assets and liabilities:
Increase (Decrease) in Operating Capital [Abstract]
Common stock, shares issued
Common Stock, Shares, Issued
Prepaid expenses and other assets
Increase (Decrease) in Prepaid Expense and Other Assets
Basis of Presentation
Business Description and Basis of Presentation [Text Block]
Remaining contractual obligation
Remaining Contractual Obligation
Remaining contractual obligation.
Income Statement [Abstract]
Entity Address, State or Province
Entity Address, State or Province
Stock purchase under ESPP
Stock Issued During Period, Value, Employee Stock Purchase Plan
Percentage of prepayment premium of principal amount outstanding thereafter prior to maturity date
Percentage Of Prepayment Premium Of Principal Amount Outstanding Thereafter
Percentage of prepayment premium of principal amount outstanding thereafter.
2022 Performance Awards [Member]
Two Thousand And Twenty Two Performance Awards [Member]
Two thousand and twenty two performance awards.
Purchases of short and long-term investments
Payments to Acquire Short-Term Investments
Minimum cash covenant waived
Line Of Credit Facility Minimum Cash Covenant Waived
Line of credit facility minimum cash covenant waived.
Portion at Fair Value Measurement [Member]
Portion at Fair Value Measurement [Member] [Default]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Axatilimab-Related Costs Membe
Axatilimab-related costs [Member]
Axatilimab-related costs [Member]
Recognized compensation expense related to stock option not met
Employee Service Share Based Compensation Recognized Stock Options Not Met
Employee service share based compensation recognized stock options not met.
Inventory, Raw Materials, Gross
Raw materials
Biopharmaceutical Cancer Therapeutics Member
Biopharmaceutical Cancer Therapeutics [Member]
Biopharmaceutical Cancer Therapeutics [Member]
Amortization of Debt Issuance Costs
Amortization of debt issuance costs
Cover [Abstract]
Subsequent Event [Line Items]
Earnings Per Share, Basic, Total
Net loss per share attributable to common stockholders—basic
Net loss per share attributable to common stockholders—basic
Earnings Per Share, Basic
Unrealized Gains
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Current portion of capital lease
Current Portion Of Capital Lease
Current portion of capital lease.
Operating expenses:
Operating Expenses [Abstract]
Share based compensation expense, total
Share-Based Payment Arrangement, Expense
2015 and 2007 [Member]
Two Thousand Seven And Two Thousand Fifteen Stock Incentive Plan [Member]
Two thousand seven and two thousand fifteen stock incentive plan.
Retained Earnings (Accumulated Deficit), Total
Accumulated deficit
Retained Earnings (Accumulated Deficit)
Plan Name
Plan Name [Axis]
Segment Reporting [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Beginning Balance
Share-based compensation, stock options outstanding
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Current assets:
Assets, Current [Abstract]
Shares available for issuance
Common Stock, Capital Shares Reserved for Future Issuance
US
UNITED STATES
Share-Based Payment Arrangement, Disclosure [Abstract]
Schedule of Prepaid Expenses and Other Current Assets
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]
Net cash used in operating activities
Net Cash Provided by (Used in) Operating Activities
Weighted Average Grant Date Fair Value, Forfeited
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number
Number of shares, Vested and exercisable, end of the period
Royalty Expense
Royalty interest expense
Royalty interest expense
Product and Service [Domain]
Debt Instrument [Line Items]
Debt Instrument [Line Items]
Property, Plant and Equipment, Net, Total
Property and equipment, net
Property, Plant and Equipment, Net
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Cash Provided by (Used in) Operating Activities [Abstract]
Schedule of Fair Values of Financial Assets and Liabilities Measured at Fair Value
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]
Common stock, par value
Common Stock, Par or Stated Value Per Share
Stock options [Member]
Unrealized (loss) gain on marketable securities
Unrealized loss on investments
Unrealized loss on investments
OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax
Unrealized gain on marketable securities
Statement of Cash Flows [Abstract]
Counterparty Name
Counterparty Name [Axis]
Antidilutive Securities, Name
Antidilutive Securities, Name [Domain]
Tranche 2 [Member]
Debt Instrument Tranche Two [Member]
Debt instrument tranche two
Warrants issued (in shares)
Class of Warrant or Right, Number of Securities Called by Warrants or Rights
Selling, General and Administrative Expenses [Member]
Selling, General and Administrative [Member]
Entity
Entity [Domain]
Capital lease, less current portion
Capital Lease Less Current Portion
Capital lease, less current portion.
Equity Components
Equity Components [Axis]
Entity Address, Address Line One
Entity Address, Address Line One
Computation of Basic and Diluted Net Loss per Share Attributable to Common Stockholders
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
Employee-related Liabilities, Current, Total
Accrued compensation and related costs
Employee-related Liabilities, Current
Number of Shares, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period
Subsequent Event Type [Axis]
Nonoperating Income (Expense)
Total other income (expense), net
Potential Dilutive Securities Excluded from Computation of Diluted Net Loss per Common Share
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
Hercules [Member]
Hercules Capital Inc [Member]
Hercules Capital, Inc.
Aggregate maximum borrowings
Line of Credit Facility, Maximum Borrowing Capacity
Ex-U.S. Countries [Member]
Non-US [Member]
US Treasury and Federal bonds [Member]
US Treasury and Government [Member]
Number of Shares, Unvested, Beginning balance
Number of Shares, Unvested, Ending balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Amendment Flag
Amendment Flag
Corporate Bonds [Member]
Corporate Debt Securities [Member]
Debt Instrument, Name
Debt Instrument, Name [Domain]
Additional paid-in capital
Additional Paid in Capital, Common Stock
Receivables [Abstract]
Net loss
Segment net loss
Proceeds from exercise of stock options, shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period
Number of shares, Exercised/Released
Stock options exercised, shares
Number of shares, Exercised/Released
Variable Rate
Variable Rate [Domain]
Research and Development [Member]
Research and Development Expense [Member]
Options grant date fair value amount
Share Based Compensation Arrangement By Share Based Payment Award Stock Option Grant Date Fair Value
Share based compensation arrangement by share based payment award stock option grant date fair value.
Schedule of Debt [Table Text Block]
Schedule of Term Loan Payables
Loans Payable, Current
Loans Payable, Current, Total
Current portion of royalty interest financing liability
Current portion of royalty interest financing liability
Incyte Corporation [Member]
Incyte Corporation [Member]
Incyte corporation.
Equity Component
Equity Component [Domain]
Statistical Measurement
Statistical Measurement [Domain]
Prepaid conference, meeting costs
Prepaid Conference, Meeting Costs
Prepaid conference, meeting costs
General and Administrative Expense, Total
General and Administrative Expense
Selling, general and administrative
Other Receivables, Net, Current [Abstract]
Interest Expense, Debt, Total
Interest expense related to the loan agreement
Interest Expense, Debt
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total
Net loss
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Upfront milestone payable
Upfront Payments
Upfront payments.
Milestone Paid
Milestone paid
Milestone Paid
Proceeds from stock option exercises
Proceeds from Stock Options Exercised
Payments for (Proceeds from) Deposit on Loan
Prepayment of loan
Payment on term loan
Payables and Accruals [Abstract]
Accrued research and development costs
Accrued Research And Development Costs
Accrued Research And Development Costs
Eddingpharm Investment [Member]
Eddingpharm Investment [Member]
Eddingpharm Investment [Member]
Stock purchase under ESPP, shares
Stock Issued During Period, Shares, Employee Stock Purchase Plans
Short-Term Investments, Total
Short-term investments
Short-Term Investments
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total
Stock option granted to certain executives, consultants and employees
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
Total prepaid expenses and other current assets
Prepaid expenses and other current assets
Prepaid Expense and Other Assets, Current
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price
Weighted Average Grant Date Fair Value, Vested and exercisable, end of the period
Proceeds from ATM sales
Stock Issued During Period Value At The Market Offering Net
Stock issued during period value at the market offering net.
Restricted cash
Restricted Cash, Noncurrent
Collaborative Arrangement and Arrangement Other than Collaborative
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Significant Agreements
Significant Agreements Disclosure [Text Block]
Significant agreements disclosure.
Common Stock, Shares, Outstanding, Ending Balance
Common Stock, Shares, Outstanding, Beginning Balance
Common stock, shares outstanding
Common Stock, Shares, Outstanding
Interest Income (Expense), Operating
Interest Income (Expense), Operating, Total
Interest expense (income), net
Interest expense (income), net
Preferred stock, par value
Preferred Stock, Par or Stated Value Per Share
Accrued Selling General and Administrative Costs
Accrued Selling General and Administrative Costs
Accrued selling, general, and administrative costs
Antidilutive Securities
Antidilutive Securities [Axis]
Employees [Member]
Employees [Member]
Employees.
Federal Bonds [Member]
Federal Bonds [Member]
Federal bonds.
Inventory, Finished Goods and Work in Process, Gross [Abstract]
Summary of Restricted Stock Units Activity
Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]
Total long-term liabilities
Liabilities, Noncurrent
Depreciation
Depreciation And Related Adjustment
Depreciation and related adjustment.
Purchase and Sale Agreement [Text Block]
Purchase and Sale Agreement [Text Block]
Royalty Interest Financing Liability
Entity Interactive Data Current
Entity Interactive Data Current
Product
Product [Member]
Lease Expiration Date
lease expiration date
Number of pre funded warrants exercised for common stock
Number Of Pre Funded Warrants Exercised For Common Stock
Number Of Pre Funded Warrants Exercised For Common Stock
Document Quarterly Report
Document Quarterly Report
Weighted Average Grant Date Fair Value, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value
Related Party Transaction
Related Party Transaction [Domain]
Statistical Measurement
Statistical Measurement [Axis]
Prepaid state and local taxes
Prepaid State and Local Taxes
Prepaid State and Local Taxes
Total assets
Assets, Fair Value Disclosure
Commercial Paper [Member]
Commercial Paper, Not Included with Cash and Cash Equivalents [Member]
Proceeds from ATM sales, shares
Stock Issued During Period Shares At The Market Offering Net
Stock issued during period shares at the market offering net.
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant
Common stock reserved for issuance
Weighted Average Grant Date Fair Value, Granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value
Weighted average period to recognize compensation expense
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition
Cost of Product Sales
Cost of Product Sales
Cost of Product Sales
Measurement Basis
Measurement Basis [Axis]
Income Statement Location
Statement of Income Location, Balance [Axis]
Michael A. Metzger [Member]
Michael A. Metzger [Member]
Michael A Metzger [Member]
Total assets
Assets
Debt Instrument [Table]
Schedule of Long-Term Debt Instruments [Table]
Number of Shares, Vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Recently Issued and Adopted Accounting Pronouncements
New Accounting Pronouncements, Policy [Policy Text Block]
Entity Address, City or Town
Entity Address, City or Town
AOCI Attributable to Parent [Member]
Accumulated Other Comprehensive(Loss) / Income [Member]
Equity [Abstract]
Cowen and Company LLC [Member]
Cowen And Company L L C [Member]
Cowen and Company LLC.
Segments [Axis]
Summary of Maturities of Principal Obligations Under Long-term Debt
Schedule of Maturities of Long-Term Debt [Table Text Block]
Number of Shares, Forfeited
Share-based compensation, stock options net of cancellations
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Prepaid Subscriptions
Prepaid Subscriptions
Prepaid subscriptions
Personnel Cost and Other Expenses
Personnel Cost and Other Expenses
Personnel cost and other expenses
Numerator—basic and diluted:
Net Income (Loss) Attributable to Parent [Abstract]
Weighted average grant date fair value per share
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value
Schedule of Segment Reporting Information, by Segment [Table]
Private Placement [Member]
Private Placement [Member]
Stock-Based Compensation
Share-Based Payment Arrangement [Text Block]
Adjustment of Warrants Granted for Services
Prefunded warrants, exercise
2019 Performance Awards [Member]
Two Thousand And Nineteen Performance Awards [Member]
Two thousand and nineteen performance awards.
Fair Value Disclosures [Abstract]
Short-term deposits
Deposits Assets, Current
Common stock issued at fair value
Stock Issued During Period, Value, New Issues
Proceeds from exercise of stock options
Stock Issued During Period, Value, Stock Options Exercised
Current liabilities:
Liabilities, Current [Abstract]
Accrued Milestone Costs
Accrued milestone costs
Accrued milestone costs
Document Type
Document Type
Gross proceeds from offering.
Gross Proceeds From Offering
Gross proceeds from offering
Title of 12(b) Security
Title of 12(b) Security
Cash and Cash Equivalents, at Carrying Value, Total
Cash and cash equivalents
Cash and Cash Equivalents, at Carrying Value
Statement of Stockholders' Equity [Abstract]
Beginning Balance 12/31/21
Ending Balance 6/30/22
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
Document Fiscal Period Focus
Document Fiscal Period Focus
Research and Development Expense, Total
Research and development expense
Research and development
Research and Development Expense
Share-based compensation, stock options granted
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross
Marketing and Advertising Expense
Marketing and Advertising Expense, Total
Commercial related expenses
Milestone Expenses Paid
Milestone Expenses Paid
Milestone Expenses Paid
Asset Class
Asset Class [Domain]
Subsequent Event Type [Domain]
Percentage of end of term charge to future draws
Percentage Of End Of Term Charge To Future Draws
Percentage of end of term charge to future draws.
Prefunded warrants, exercise, shares
Exercise of prefunded warrants shares.
Exercise Of Prefunded Warrants, Shares
Sale of Stock
Sale of Stock [Axis]
CASH FLOWS FROM INVESTING ACTIVITIES:
Net Cash Provided by (Used in) Investing Activities [Abstract]
Current portion of royalty interest financing liability
Current portion of royalty interest financing liability
Current portion of royalty interest financing liability
Earnings Per Share Basic [Line Items]
Earnings Per Share, Basic, by Common Class, Including Two Class Method [Line Items]
Total revenues
Revenue from Contract with Customer, Excluding Assessed Tax
Total Revenue
Total revenues
Product Revenue Allowance
Product Revenue Allowance
Product revenue allowances
Credit Facility
Credit Facility [Domain]
Debt Securities Available For Sale [Table]
Debt Securities, Available-for-Sale [Table]
Other Accrued Liabilities, Current
Other
Increase (Decrease) in Accounts Payable, Total
Accounts payable
Increase (Decrease) in Accounts Payable
Entity Address, Address Line Two
Entity Address, Address Line Two
LIABILITIES AND STOCKHOLDERS’ EQUITY
Liabilities and Equity [Abstract]
Document Period End Date
Document Period End Date
Net cash provided by financing activities
Net Cash Provided by (Used in) Financing Activities
Term Loan [Member]
Term Loan [Member]
Term loan.
Long-term liabilities:
Liabilities, Noncurrent [Abstract]
Stock Issued During Period, Shares, Restricted Stock Award, Gross
Vesting of RSUs
Anti-dilutive securities excluded from computation of diluted net loss per common share
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
Carrying Value [Member]
Reported Value Measurement [Member]
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total
Stock-based compensation expense
APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
Par value adjustment
Par Value Adjustments
Par Value Adjustments
Other Research and Development Expense
Other R&D programs
Other Nonoperating Expense
Other expense
Income Tax Expense (Benefit)
Income Tax Expense Benefit
Trading Symbol
Trading Symbol
Variable Rate
Variable Rate [Axis]
Total stockholders’ equity
Beginning balance
Ending balance
Equity, Attributable to Parent
License expiration year
License Agreements Expiration Period
License agreements expiration period.
Vesting of RSUs, shares
Vesting of Restricted Stock Units, Shares
Vesting of Restricted Stock Units, Shares
Warrants Outstanding
Class of Warrant or Right, Outstanding
Collaboration Payable, Current
Collaboration Payable, Current
Collaboration payable, net
Collaboration Payable, Current, Total
Collaboration receivable
Collaboration receivable, net
Collaboration receivable
Collaboration receivable
Restricted Stock Units [Member]
Non-Vested Restricted Stock Units (RSUs) [Member]
Restricted Stock Units (RSUs) [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total
Unrecognized compensation expense related to stock option and RSUs
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount
Share Based Compensation Expense Related to Issuance of Stock Option Awards to Employees and Non Employees Related to Employee Stock Purchase Plan
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
Available through November 30, 2022 [Member]
Scenario Two [Member]
Scenario two.
Nature of Business
Nature of Operations [Text Block]
Defined Contribution Plan, Employer Discretionary Contribution Amount
Contributions by the company
Geographical
Geographical [Axis]
Tranche 3 [Member]
Debt Instrument Tranche Three [Member]
Debt instrument, tranche three.
Unrealized Losses
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Share based compensation
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
Loan Processing Fee
Upfront fee
Upfront fee
Use of Estimates
Use of Estimates, Policy [Policy Text Block]
Dennis Podlesak [Member]
Dennis Podlesak [Member]
Dennis Podlesak [Member]
Milestone payment payable
Milestone Payment Due
Milestone payment due.
Other Operating Income (Expense), Net
Other expense, net
First Amendment to Loan Agreement [Member]
First Amendment To Loan And Security Agreement [Member]
First amendment to loan and security agreement.
License Agreement [Member]
License Agreement [Member]
License agreement.
Fair Value Measurements
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]
Class of Stock [Line Items]
Class Of Stock [Line Items]
Class of Stock [Line Items]
Liability related to letter agreement
Liability Related To Letter Agreement
Liability related to letter agreement.
Retail Land Sales Receivables, Stated Interest Rate
Percentage of net sales
Scenario
Scenario [Axis]
Security Exchange Name
Security Exchange Name
Counterparty Name
Counterparty Name [Domain]
Total operating expenses
Operating Expenses
Collaboration expense due to counterparty
Collaboration Expense Due To Counterparty
Collaboration expense due to counterparty.
Legal Entity
Legal Entity [Axis]
Employee withholdings ESPP
Employee withholdings ESPP
Employee withholdings ESPP
Development costs associated with clinical trials
Development Costs Associated With Clinical Trials
Development costs associated with clinical trials.
Weighted average grant date fair value of options
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Interest receivable on investments
Interest Receivable, Current
Subsequent Event [Member]
Maximum [Member]
Maximum [Member]
Total liabilities and stockholders’ equity
Liabilities and Equity
Right-of-use asset, net
Operating Lease, Right-of-Use Asset
Wall Street Journal Prime Rate [Member]
Prime Rate [Member]
Earnings Per Share, Diluted, Total
Net loss per share attributable to common stockholders— diluted
Net loss per share attributable to common stockholders—diluted
Earnings Per Share, Diluted
Dividends, Total
Deemed dividend due to warrant reset
Dividends
Total liabilities
Liabilities
Research and Development [Abstract]
Fair Value Hierarchy and NAV
Fair Value Hierarchy and NAV [Domain]
Increase (Decrease) in Accounts Receivable and Other Operating Assets
Other receivable
Other receivable
Total current assets
Assets, Current
Interest rate description
Line of Credit Facility, Interest Rate Description
Net Cash Provided by (Used in) Investing Activities
Net cash provided by investing activities
Deemed dividend due to warrant reset
Warrant, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount
Scenario Forecast [Member]
Forecast [Member]
Common stock, new shares issued
Common stock shares purchased
Stock Issued During Period, Shares, New Issues
Entity Filer Category
Entity Filer Category
Royalty interest financing liability, less current portion
Royalty interest financing liability, less current portion
Royalty interest financing liability, less current portion
Net loss attributable to common stockholders - diluted
Net loss attributable to common stockholders - diluted
Net Income (Loss) Available to Common Stockholders, Diluted
Other income (expense), net:
Nonoperating Income (Expense) [Abstract]
Employee Stock Purchase Plan [Member]
Employee Stock Purchase Plan [Member]
Employee stock purchase plan.
Current Fiscal Year End Date
Current Fiscal Year End Date
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Period of contractual obligation
Contractual Obligations Term
Contractual obligations term.
Capped Funded Amount
Capped Funded Amount
Capped funded amount
Share-Based Payment Arrangement, Noncash Expense, Total
Stock-based compensation
Share-Based Payment Arrangement, Noncash Expense
Change in fair value
Change in fair value
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value
Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Change In Fair Value
Legal Fees
Bank and legal fees
Related Party Transaction
Related Party Transaction [Axis]
Minimum cash covenant
Line Of Credit Facility Minimum Cash Covenant
Line of credit facility minimum cash covenant.
Purchase and Sale Agreement [Abstract]
Purchase and Sale Agreement [Abstract]
Stock based compenstion
Stock based compenstion
Stock-based compenstion
Payments for Other Fees
Pre-Payment Fees
Entity Registrant Name
Entity Registrant Name
Contingent liabilities
Business Combination, Contingent Consideration, Liability
Business Combination, Contingent Consideration, Liability, Total
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Net Loss per Share Attributable to Common Stockholders
Earnings Per Share [Text Block]
Entity Emerging Growth Company
Entity Emerging Growth Company
Weighted Average Number of Shares Outstanding, Basic, Total
Weighted-average number of common shares used to compute net loss per share attributable to common stockholders—basic
Weighted-average number of common shares used to compute net loss per share attributable to common stockholders —basic
Weighted Average Number of Shares Outstanding, Basic
Schedule Of Earnings Per Share Basic By Common Class [Table]
Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]
Common stock, shares authorized
Common Stock, Shares Authorized
Proceeds from issuance of common stock
Proceeds from issuance of common stock in at-the-market stock offering, net
Proceeds from issuance of common stock in follow-on public stock offering, net
Potential milestone payments to be made
Potential Milestone Payments Upon Achievement Of Milestone
Potential milestone payments upon achievement of milestone.
Not to Draw First from Tranche 2 [Member]
Scenario Three [Member]
Scenario Three.
Quoted Prices (Unadjusted) in Active Markets Level 1 [Member]
Fair Value, Inputs, Level 1 [Member]
Debt Disclosure [Abstract]
Share-Based Payment Arrangement [Abstract]
Debt, Current
Total royalty interest financing liability, net
Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Development and regulaotry milestones Expenses
Development and regulaotry milestones Expenses
Development and regulaotry milestones Expenses
Debt Securities, Available-for-Sale, Total
Fair Value
Debt Securities, Available-for-Sale
Accounting Policies [Abstract]
Stockholders’ equity:
Equity, Attributable to Parent [Abstract]
Percentage of prepayment premium of principal amount outstanding in second year
Percentage Of Prepayment Premium Of Principal Amount Outstanding In Second Year
Percentage of prepayment premium of principal amount outstanding in second year.
2015 Plan [Member]
Two Thousand Fifteen Omnibus Incentive Plan [Member]
Two thousand fifteen omnibus incentive plan.
Statement [Table]
Statement [Table]
Purchase and Sale Agreement [Line Items]
Purchase and Sale Agreement [Line Items]
UCB Biopharma [Member]
U C B Biopharma [Member]
UCB Biopharma.
Subsequent Event [Table]
Up-front license fee paid
Upfront License Fees Paid
Upfront license fees paid.
Vitae Pharmaceuticals Inc [Member]
Vitae Pharmaceuticals Inc [Member]
Vitae Pharmaceuticals, Inc.
Preferred stock, shares authorized
Preferred Stock, Shares Authorized
Revumenib-related costs [Member]
Revumenib-related costs [Member]
Revumenib-Related Costs Member
Incyte Collaboration Agreement and Share Purchase Agreement [Member]
Incyte Collaboration Agreement And Share Purchase Agreement [Member]
Incyte collaboration agreement and share purchase agreement.
Entity File Number
Securities Act File Number
Segment Reporting
Segment Reporting Disclosure [Text Block]
Pre-funded warrants exchange
Number Of Pre Funded Warrants Exchanged For Common Stock
Number of pre-funded warrants exchanged for common stock.
NET (DECREASE) INCREASE CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
Earnings Per Share [Abstract]
Inventory Disclosure [Abstract]
Other Receivables
Other receivable
Statement of Financial Position [Abstract]
Bayer Pharma AG [Member]
Bayer Pharma Ag [Member]
Bayer Pharma AG .
Non-cash operating lease expense
Noncash Operating Lease Expense
Non-cash operating lease expense.
Interest Expense, Operating and Nonoperating
Interest Expense, Operating and Nonoperating, Total
Interest expense
Loss from operations
Operating Income (Loss)
Purchase price per share
Shares Issued, Price Per Share
At-the-Market Offering [Member]
At The Market Stock Offering [Member]
At the market stock offering.
Entity Shell Company
Entity Shell Company
Accrued professional fees
Accrued Professional Fees, Current
Personnel cost and other expenses
Personnel cost and other General expenses
Personnel cost and other General expenses
Accrued Royalty Interest Expense
Accrued Royalty Interest Expense
Accrued royalty interest expense
Debt Instrument, Interest Rate, Effective Percentage
Company effective annual interest rate
Entity Tax Identification Number
Entity Tax Identification Number
Assets [Abstract]
ASSETS
Accrued clinical study and trial costs
Accrued Clinical Costs Current
Accrued clinical costs current.
Entity Current Reporting Status
Entity Current Reporting Status
Net loss attributable to common stockholders
Net loss attributable to common stockholders - basic
Net Income (Loss) Available to Common Stockholders, Basic
Research And Development Arrangement Contract To Perform For Others [Line Items]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Debt Securities, Available-for-Sale, Realized Gain (Loss), Total
Realized gains or losses recognized on the sale or maturity of available-for-sale securities
Debt Securities, Available-for-Sale, Realized Gain (Loss)
Schedule of Accrued Expenses and Other Current Liabilities
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]
Subsequent Events [Abstract]
Inventory Disclosure [Text Block]
Inventory
Geographical
Geographical [Domain]
Document Fiscal Year Focus
Document Fiscal Year Focus
2007 Plan [Member]
Two Thousand And Seven Stock Incentive Plan [Member]
Two thousand and seven stock incentive plan.
Other General and Administrative Expense
Other SG&A expenses
Prepaid Expenses and Other Current Assets
Other Current Assets [Text Block]
Preferred Stock, Value, Issued
Preferred stock, $0.001 par value, 10,000,000 shares authorized; 0 shares outstanding at March 31, 2025 and December 31, 2024
Payment for end-of term fees
Payment for end-of term fees
End-of Term fees
Allergan License Agreement Member
Allergan License Agreement [Member]
Allergan license agreement.
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total
CASH, CASH EQUIVALENTS AND RESTRICTED CASH—beginning of period
CASH, CASH EQUIVALENTS AND RESTRICTED CASH —end of period
Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations
Long-term investments
Long-Term Investments
Long-Term Investments, Total
City Area Code
City Area Code
Increase decrease in collaboration receivable.
Increase Decrease In Collaboration Receivable
Collaboration receivable, net
Collaboration (payable) receivable, net
Total current liabilities
Liabilities, Current
Accrued contractual obligation
Accrued Contractual Obligation
Accrued contractual obligation.
Total accrued expenses and other current liabilities
Accrued expenses and other current liabilities
Accrued Liabilities and Other Liabilities
Line of Credit Facility, Lender
Line of Credit Facility, Lender [Domain]
Inventory, Net
Inventory
Total Inventory
Collaboration Loss
Collaboration Loss
Collaboration Loss
Inventory, Finished Goods, Gross
Inventory, Finished Goods
Finished goods
Loan And Security Agreement [Member]
Loan Agreement [Member]
Loan and security agreement.
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Local Phone Number
Local Phone Number
Preferred Stock, Shares Outstanding, Ending Balance
Preferred Stock, Shares Outstanding, Beginning Balance
Preferred stock, shares outstanding
Preferred Stock, Shares Outstanding
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Prepaid Inventory
Prepaid Inventory
Prepaid inventory
Pre-funded warrants cashless exchange
Number Of Pre Funded Warrants Cashless Exchanged For Common Stock
Number of pre funded warrants cashless exchanged for common stock.
Income Tax, Policy [Policy Text Block]
Income taxes
Other Receivables [Text Block]
Other Receivables [Text Block]
Other Receivables
Commitments and Contingencies Disclosure [Abstract]
Debt Issuance Costs, Net
Debt issuance costs
Debt Issuance Costs, Net, Total
Debt issuance costs
Amortized Cost
Debt Securities, Available-for-Sale, Amortized Cost
Current portion of right-of-use liability
Operating Lease, Liability, Current
Percentage of prepayment premium of principal amount outstanding in first year
Percentage Of Prepayment Premium Of Principal Amount Outstanding In First Year
Percentage of prepayment premium of principal amount outstanding in first year.
Two Thousand Twenty Three Inducement Incentive Plan [Member]
Two Thousand Twenty Three Inducement Incentive Plan [Member]
2023 Inducement Plan [Member]
Percentage of Net Sales to Royalty Rate
Percentage of Net Sales to Royalty Rate
Percentage of net sales to royalty rate
Pre Funded Warrants [Member]
Pre Funded Warrants [Member]
Pre funded warrants.
Fair Value Measurements [Table]
Fair Value Measurements [Table]
Fair Value Measurements [Table]
Interest rate
Debt Instrument, Interest Rate, Stated Percentage
ATM Offering, offering cost
Stock Issued During Period Value At The Market Offering Expenses
Stock issued during period value at the market offering expenses.
Accumulated Deficit [Member]
Retained Earnings [Member]
Document Transition Report
Document Transition Report
Available through April 30, 2022 [Member]
Scenario One [Member]
Scenario one.
Aggregate potential milestone payable
Aggregate Potential Milestone Payable
Aggregate potential milestone payable.
Global and U.S. [Member]
Global And United States [Member]
Global and united states.
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]
Antidilutive Security, Excluded EPS Calculation [Table]
Proceeds from Employee Stock Purchase Plan
Proceeds from Stock Plans
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Weighted Average Grant Date Fair Value, Exercised/Released
Minimum [Member]
Minimum [Member]
Warrants to Purchase Common Stock [Member]
Warrants To Purchase Common Stock [Member]
Warrants to purchase common stock.
Common Stock [Member]
Common Stock [Member]
Summary of Changes in Stockholders' Equity
Schedule of Stockholders Equity [Table Text Block]
Revenue recognition milestone
Revenue Recognition Milestone
Revenue milestone
Weighted Average Grant Date Fair Value, Unvested, Ending Balance
Weighted Average Grant Date Fair Value, Unvested, Beginning balance
Weighted Average Grant Date Fair Value, Unvested, Beginning balance
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Additional Paid-In Capital [Member]
Additional Paid-in Capital [Member]
Purchase and Sale Agreement [Member]
Purchase and Sale Agreement [Member]
Adjustments to reconcile net loss to net cash used in operating activities:
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Income Statement Location
Statement of Income Location, Balance [Domain]
Increase in contractual obligation
Increase Decrease In Contractual Obligation
Increase decrease in contractual obligation.
Non refundable cash payments.
Non Refundable Cash Payments [Member]
Non-Refundable Cash Payments [Member]
Segments [Domain]
Other
Other Prepaid Expense, Current
At The Market Equity Offering Sales Agreement [Member]
At The Market Equity Offering Sales Agreement [Member]
At the market equity offering sales agreement.
Schedule of Inventory, Current [Table Text Block]
Schedule of Consisted Inventroies
Entity Common Stock, Shares Outstanding
Entity Common Stock, Shares Outstanding
Accrued expenses and other liabilities
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Royalty Payable
Royalty Payable
Royalty payable
Significant Accounting Policies
Basis of Accounting, Policy [Policy Text Block]
Scenario
Scenario [Domain]
Title of Individual
Title and Position [Domain]
Par value adjustment
Common Stock, Value, Issued
Common stock, $0.0001 par value, 200,000,000 shares authorized; 86,047,032 and 85,694,443 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Interest income
Investment Income, Interest
Prepaid insurance
Prepaid Insurance
Prepaid Rent
Prepaid rent
Cash and cash equivalents
Cash and Cash Equivalents, Fair Value Disclosure
Fair Value Measurements [Line Items]
Fair Value Measurements [Line Items]
Fair value measurements.
Eastern Cooperative Oncology Group [Member]
Eastern Cooperative Oncology Group [Member]
Eastern Cooperative Oncology Group.
Summary of Available-for-Sale Securities
Debt Securities, Available-for-Sale [Table Text Block]
Commitments and Contingencies
Commitments and contingencies (Note 14)
Weighted-average number of common shares used to compute net loss per share attributable to common stockholders—diluted
Weighted Average Number of Shares Outstanding, Diluted, Total
Weighted-average number of common shares used to compute net loss per share attributable to common stockholders—diluted
Weighted Average Number of Shares Outstanding, Diluted
Summary of Significant Accounting Policies
Significant Accounting Policies [Text Block]
Schedule of Segment Reporting Information, by Segment [Table Text Block]
Schedule of Operating Financial Results
Share-based compensation, stock options vested
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Inventory
Increase (Decrease) in Inventories
Increase (Decrease) in Inventories, Total
Inventory
Incyte Agreement [Member]
Collaboration And License Agreement [Member]
Collaboration and license agreement.
Denominator—basic and diluted:
Weighted Average Number of Shares Outstanding, Diluted [Abstract]
Entity Small Business
Entity Small Business
Segment Reporting Information [Line Items]
Basis spread on variable rate
Debt Instrument, Basis Spread on Variable Rate
Commercialization milestones and tiered royalties
Commercialization Milestones And Tiered Royalties
Commercialization milestones and tiered royalties.
Employee withholdings ESPP
Adjustment To Additional Paid In Capital Employee Withholdings Employee Stock Purchase Plan
Adjustment to additional paid in capital employee withholdings employee stock purchase plan.
Loan Payable
Debt Disclosure [Text Block]
Significant Collaborative Research and License Agreements
Collaborative Research And License Agreements [Text Block]
Collaborative research and license agreements.
U.S. Treasury [Member]
US Treasury Securities [Member]
Derivative Liability, Total
Derivative liability
Derivative Liability
Available For Sale Securities Fair Value Disclosure [Abstract]
Available For Sale Securities Fair Value Disclosure [Abstract]
Credit Facility
Credit Facility [Axis]
Accounts and Other Receivables, Net, Current
Accounts receivable, net
Derivative Liability:
Derivative Liability [Abstract]
Contractual Obligation, Total
Aggregate payment obligation
Contractual Obligation
Accretion of investments
Accretion (Amortization) of Discounts and Premiums, Investments
CASH FLOWS FROM FINANCING ACTIVITIES:
Net Cash Provided by (Used in) Financing Activities [Abstract]
Accrued Expenses and Other Current Liabilities
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]
Asset Class [Axis]
Asset Class
Series warrants.
Series Warrants [Member]
Series Warrants [Member]
Payments for Participation Liabilities
Revenue participation right
Work-in-process
Inventory, Work in Process, Gross
Significant Unobservable Inputs Level 3 [Member]
Fair Value, Inputs, Level 3 [Member]
Vesting period, description
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights
Subsequent Events [Text Block]
Subsequent Events
Accounts Payable, Current, Total
Accounts payable
Accounts Payable, Current
Total liabilities
Liabilities, Fair Value Disclosure